Advertisement

Topics

More News! Novartis is going for EMA Approval for CAR-T Therapy

06:00 EST 10 Nov 2017 | Labiotech.eu

Try as we might, we can’t cover all the biotech news out there! Here’s a roundup of news that didn’t make the cut this week. Allergan has returned development rights to Heptares for its muscarinic M1 agonist designed to treat Lewy body-based dementia. In ...

This awesome article More News! Novartis is going for EMA Approval for CAR-T Therapy appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)

Original Article: More News! Novartis is going for EMA Approval for CAR-T Therapy

NEXT ARTICLE

More From BioPortfolio on "More News! Novartis is going for EMA Approval for CAR-T Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...